The docetaxel polymeric form and its antitumor activity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A new pharmaceutical form of the antitumor drug docetaxel (Dtx) has been developed based on a biodegradable copolymer of lactic and glycolic acids (PLGA 50/50). This form was constituted of polymeric particles (250 to 300 nm in size) and was highly active against mouse mammary adenocarcinoma (Ca755) and human breast adenocarcinoma (MCF-7Wt) cell lines. The results of the in vivo studies carried out on the C57Bl/6 female mice line showed an increase in the life span of the animals treated with the polymeric particles. Furthermore, the polymeric drug at a dose of 10 mg/kg and the drug substance at a dose of 20 mg/kg manifested a similar effect. At the same time, the acute toxicity of the Dtx polymeric form was 2.3 times lower than that of the drug substance.

About the authors

E. D. Nikolskaya

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
Russian Federation, Moscow, 117149

O. A. Zhunina

JSC Russian Research Center for Molecular Diagnostics and Therapy

Author for correspondence.
Email: olga_yarova@bk.ru
Russian Federation, Moscow, 117149

N. G. Yabbarov

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
Russian Federation, Moscow, 117149

O. G. Tereshchenko

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
Russian Federation, Moscow, 117149

A. V. Godovannyy

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
Russian Federation, Moscow, 117149

N. V. Gukasova

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
Russian Federation, Moscow, 117149

E. S. Severin

JSC Russian Research Center for Molecular Diagnostics and Therapy

Email: olga_yarova@bk.ru
Russian Federation, Moscow, 117149


Copyright (c) 2017 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies